Assessment of the Effects of a Daily Supplement 4Life Transfer Factor Vista Containing AREDS2 Formula on Skin Carotenoid Levels Using a Non-invasive Detection
Assessment of the Effects of a Daily Supplement 4Life Transfer Factor Vista Containing the AREDS2 Formula on Skin Carotenoid Levels Using a Non-Invasive Method
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Utah
-
Sandy City, Utah, United States, 84070
- 4Life Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy subjects ≥ 18 years of age. Committed to maintain the same eating, exercise, and other lifestyle routines for the whole duration of the study.
Exclusion Criteria:
- • Pregnant and/or lactating women or planning to become pregnant in the following 12 weeks.
- Participants were not allowed to participate if they have a known allergy or adverse reaction to any of the ingredients in the study product.
- Participants were not allowed to participate if they have used AREDS2 formula products over the past 6 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 4lLife TF Vista
Participants were supplied with two bottles of the study product (for Cohort-1) and three bottles (for Cohort-2) labeled with the participant number during the study.
They were required to take the product consisting of 4 capsules per day, taken with 8 oz. of fluid and preferably with a meal.
|
Study product 4Life TF Vista contains Tri Factor (bovine colostrum and egg yolk), bilberry (Vaccinium myrtillus) fruit powder, black currant (Ribes Nigrum) powder, lutein, zeaxanthin (Tagetes erecta), vitamin C, vitamin A, vitamin E, zinc, and copper.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin Carotenoid Levels
Time Frame: From enrollment to the end of treatment at 8 weeks for Cohort-1 and 12 weeks for Cohort-2
|
Skin carotenoid levels measured via a portable Veggie Meter, Longevity Link Corp. device using reflection spectroscopy on a participant's fingerprint.
|
From enrollment to the end of treatment at 8 weeks for Cohort-1 and 12 weeks for Cohort-2
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Antioxidant Levels
Time Frame: From enrollment to the end of treatment at 8 weeks for Cohort-1 and 12 weeks for Cohort-2.
|
Antioxidant levels assessed by a Samsung Watch device via skin absorption spectra.
The bioactive sensor measures reflected light after emitting LED light.
The test requires the participant to press the thumb on the sensor for a few seconds to get a reading.
|
From enrollment to the end of treatment at 8 weeks for Cohort-1 and 12 weeks for Cohort-2.
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Macular Pigment Optical Density (MPOD)
Time Frame: At enrollment and at the end of the treatment (week-12)
|
Macular Pigment Optical Density (MPOD) testing measurement of the density of the light-absorbing pigments in the center of the retina.
This tests is performed only for participants in Cohort-2.
|
At enrollment and at the end of the treatment (week-12)
|
|
Visual Acuity Test
Time Frame: From enrollment to the end of treatment at 8 weeks.
|
Visual Acuity Test to measure sharpest vision using a Snellen eye chart, to determine the smallest detail a participant can see from 20 feet distance.
Test will be performed only for participants included in Cohort-1
|
From enrollment to the end of treatment at 8 weeks.
|
|
Amsler Grid Chart Test
Time Frame: From enrollment to the end of treatment at 8 weeks.
|
Amsler Grid Chart Test to monitor central vision for changes like way, blurry, or missing lines.
Test performed only on participants included in Cohort-1.
|
From enrollment to the end of treatment at 8 weeks.
|
|
Visual Functioning Questionnaire-25 (VFQ-25)
Time Frame: From enrollment to the end of treatment at 8 weeks.
|
Visual Functioning Questionnaire-25 (VFQ-25) to assess participants self-reported vision- related quality of life.
For participants included in Cohort-1.
|
From enrollment to the end of treatment at 8 weeks.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: David Vollmer, 4Life Research
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 4LIFE2026-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.